The Rheumatologist
COVID-19 News
  • Connect with us:
  • Facebook
  • Twitter
  • LinkedIn
  • YouTube
  • Feed
  • Home
  • Conditions
    • Rheumatoid Arthritis
    • SLE (Lupus)
    • Crystal Arthritis
      • Gout Resource Center
    • Spondyloarthritis
    • Osteoarthritis
    • Soft Tissue Pain
    • Scleroderma
    • Vasculitis
    • Systemic Inflammatory Syndromes
    • Guidelines
  • Resource Centers
    • Axial Spondyloarthritis Resource Center
    • Gout Resource Center
    • Psoriatic Arthritis Resource Center
    • Rheumatoid Arthritis Resource Center
    • Systemic Lupus Erythematosus Resource Center
  • Drug Updates
    • Biologics & Biosimilars
    • DMARDs & Immunosuppressives
    • Topical Drugs
    • Analgesics
    • Safety
    • Pharma Co. News
  • Professional Topics
    • Ethics
    • Legal
    • Legislation & Advocacy
    • Career Development
      • Certification
      • Education & Training
    • Awards
    • Profiles
    • President’s Perspective
    • Rheuminations
    • Interprofessional Perspective
  • Practice Management
    • Billing/Coding
    • Quality Assurance/Improvement
    • Workforce
    • Facility
    • Patient Perspective
    • Electronic Health Records
    • Apps
    • Information Technology
    • From the College
    • Multimedia
      • Audio
      • Video
  • Resources
    • Issue Archives
    • ACR Convergence
      • Systemic Lupus Erythematosus Resource Center
      • Rheumatoid Arthritis Resource Center
      • Gout Resource Center
      • Abstracts
      • Meeting Reports
      • ACR Convergence Home
    • American College of Rheumatology
    • ACR ExamRheum
    • Research Reviews
    • ACR Journals
      • Arthritis & Rheumatology
      • Arthritis Care & Research
      • ACR Open Rheumatology
    • Rheumatology Image Library
    • Treatment Guidelines
    • Rheumatology Research Foundation
    • Events
  • About Us
    • Mission/Vision
    • Meet the Authors
    • Meet the Editors
    • Contribute to The Rheumatologist
    • Subscription
    • Contact
  • Advertise
  • Search
You are here: Home / Articles / Rheumatology Drug Updates: Ixekizumab Improves Work Productivity, plus Vobarilizumab Completes Phase 2 Trial in Rheumatoid Arthritis

Rheumatology Drug Updates: Ixekizumab Improves Work Productivity, plus Vobarilizumab Completes Phase 2 Trial in Rheumatoid Arthritis

September 9, 2016 • By Michele B. Kaufman, PharmD, BCGP

  • Tweet
  • Email
Print-Friendly Version / Save PDF

Ixekizumab Improves Work Productivity in Patients with Plaque Psoriasis

Indirect costs of reduced work productivity can have a significant impact on a patient’s quality of life. A recent article published in JAMA Dermatology analyzed the results of three multicenter, randomized double-blind Phase 3 trials, UNCOVER-1, UNCOVER-2 and UNCOVER-3, which evaluated the effect of ixekizumab on work productivity in patients with moderate to severe plaque psoriasis.1

You Might Also Like
  • Ixekizumab Improves Work Productivity in Patients with Plaque Psoriasis
  • Plaque Psoriasis: Secukinumab Beats Ustekinumab in a Head-to Head Clinical Trial & Ixekizumab Helps Improve Productivity
  • Clinical Trial of Ixekizumab for Psoriatic Arthritis Shows Positive Results
Explore This Issue
September 2016
Also By This Author
  • Certolizumab Pegol Receives FDA Approval for Plaque Psoriasis

Researchers used the Work Productivity and Activity Impairment–Psoriasis Questionnaire (WPAI-PSO), which asks six questions about work and the effects of psoriasis for the seven days prior to completing the questionnaire. It assesses current employment (yes/no), psoriasis-related missed time from work in hours, missed time from work for other reasons in hours, time actually worked in hours, the effect of psoriasis while working on a 0–10 point scale, and the effect of psoriasis on daily activities on a 0–10 point scale. From this survey, four scores were used to identify the impact of a patient’s psoriasis on their work productivity: percentage of absenteeism, percentage of presenteeism, percentage of work productivity loss and percentage of activity impairment. The secondary endpoint in all three studies was to measure the change from baseline of WPAI-PSO scores in ixekizumab-treated patients against a comparator. Higher scores meant greater impairment.

ad goes here:advert-1
ADVERTISEMENT
SCROLL TO CONTINUE

Across all trials, 5,101 patients consented, and 3,866 were randomized. The majority of patients were male (67–68%), with an average age of 45 years.

In the UNCOVER-1 trial, patients were randomized 1:1:1 to receive subcutaneous placebo, 80 mg ixekizumab subcutaneously every two weeks or 80 mg ixekizumab subcutaneously every four weeks for 12 weeks. Both the UNCOVER-2 and UNCOVER-3 trials had an etanercept arm in which patients received 50 mg etanercept twice weekly. Maintenance of initial ixekizumab response was evaluated in UNCOVER-1 and UNCOVER-2 during a randomized withdrawal period following Week 12 through Week 60. The WPAI-PSO questionnaire was completed at baseline and Week 12 for all patients. The WPAI-PSO was also administered to patients in the UNCOVER-1 and UNCOVER-2 trials at Weeks 24, 36, 52 and 60.

ad goes here:advert-2
ADVERTISEMENT
SCROLL TO CONTINUE

Indirect costs of reduced work productivity can have a significant impact on a patient’s quality of life.

In UNCOVER-1 at Week 12, the groups taking ixekizumab every four weeks and ixekizumab every two weeks showed significantly greater improvements in WPAI-PSO scores for absenteeism, presenteeism, work productivity loss and activity impairment compared with placebo-treated patients. The results of UNCOVER-2 and UNCOVER-3 were similar, except for absenteeism for patients treated with ixekizumab every four weeks. Additionally, ixekizumab-treated patients had significantly greater WPAI-PSO score improvement compared with etanercept-treated patients at Week 12, which was maintained to Week 60.

Pages: 1 2 3 | Single Page

Filed Under: Conditions, Drug Updates Tagged With: drug update, ixekizumab, outcome, productivity, Psoriasis, Research, result, Rheumatoid arthritis, rheumatology, Safety, trial, vobarilizumabIssue: September 2016

You Might Also Like:
  • Ixekizumab Improves Work Productivity in Patients with Plaque Psoriasis
  • Plaque Psoriasis: Secukinumab Beats Ustekinumab in a Head-to Head Clinical Trial & Ixekizumab Helps Improve Productivity
  • Clinical Trial of Ixekizumab for Psoriatic Arthritis Shows Positive Results
  • FDA Updates Ixekizumab Label to Include Genital Area Psoriasis

Simple Tasks

Learn more about the ACR’s public awareness campaign and how you can get involved. Help increase visibility of rheumatic diseases and decrease the number of people left untreated.

Visit the Simple Tasks site »

Rheumatology Research Foundation

The Foundation is the largest private funding source for rheumatology research and training in the U.S.

Learn more »

ACR Convergence

Don’t miss rheumatology’s premier scientific meeting for anyone involved in research or the delivery of rheumatologic care or services.

Visit the ACR Convergence site »

The Rheumatologist newsmagazine reports on issues and trends in the management and treatment of rheumatic diseases. The Rheumatologist reaches 11,500 rheumatologists, internists, orthopedic surgeons, nurse practitioners, physician assistants, nurses, and other healthcare professionals who practice, research, or teach in the field of rheumatology.

About Us / Contact Us / Advertise / Privacy Policy / Terms of Use

  • Connect with us:
  • Facebook
  • Twitter
  • LinkedIn
  • YouTube
  • Feed

Copyright © 2006–2022 American College of Rheumatology. All rights reserved.

ISSN 1931-3268 (print)
ISSN 1931-3209 (online)